While it is fair to say the biotech sector has started to feel the effects of a softening of investor risk appetite, the muted investor appetite for biotech is also perhaps due to the sector entering something of a transitional phase.
The larger commercial-stage companies that led the sector's strong performance over the past few years have matured to resemble their slower-growing pharmaceutical peers. In contrast, investor enthusiasm...
To continue under same brands
Growth still strong and valuations attractive
Was CEO of TeamBlockchain
Joe McDonnell joins as head of portfolio solutions (EMEA)
Latest edition of the print magazine online